KLOW Blend (KPV + GHK-Cu + BPC-157 + TB-500) Pricing: September 2026

The price picture as of September 2, 2026. KLOW is an 80 mg vial of 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. It adds KPV to the older three-peptide GLOW mix. The cheap end of the research market has vanished since April. Empower Peptides, then $41 to $52 a vial, now lists $90; Ameano moved from $90 to $98; Bluum went from $120 to $139 and is sold out. The premium tier fell instead, with BioLongevity Labs cutting its $274.97 vial to $137.49 on sale. The one clinic with public prices, Better Med Spa in Chicago, still charges $400 for four weeks and $690 for eight. Research vials are labeled research use only and are not for human use; the tables include them for market context.

Three of the four peptides passed PCAC; one waits. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157 (8-6-1), KPV (8-6-1), and TB-500 (8-6) for the Section 503A bulks list, which names the raw ingredients a licensed pharmacy may use to compound a drug for one named patient. Section 503B is the bulk-batch route and has its own list. GHK-Cu was not on the July agenda; the FDA has scheduled a second PCAC peptide meeting before the end of February 2027, and GHK-Cu is one of five substances on that docket. So a fully legal, compounded KLOW is at least two rulemakings away.

A vote is not a rule. PCAC advises, and the FDA still has to publish a proposed rule for each peptide, take comments, and finalize it before anything changes. Holland & Knight's August 4 legal note said the recommended peptides "still cannot be lawfully compounded," and no proposed rule had appeared by the end of August. The Chicago and Kansas clinics below were prescribing KLOW before the vote and have not changed their pages since. Our piece The FDA panel voted yes on BPC-157 and KPV, but compounding is still not legal covers what has to happen next, and KPV now has its own guide: KPV pricing: September 2026.

What KPV adds. KPV (lysine-proline-valine) is a three-amino-acid fragment of the hormone alpha-MSH. In lab and animal studies it damps two inflammation signals inside cells, NF-kB and MAPK. It also enters gut cells through a transporter (PepT1) that inflamed tissue makes more of, which is the argument for KLOW over GLOW when the gut or skin is inflamed. Human trial evidence is thin, and FDA's own reviewers said so before the vote. The usual protocol dissolves an 80 mg vial in 3 mL of bacteriostatic water and injects 200 to 500 mcg of blend a day for 8 to 12 weeks. Australia's Therapeutic Goods Administration named GHK-Cu, BPC-157, and TB-500, three of KLOW's four parts, in its June 2026 enforcement push on unapproved peptides. For the six PCAC-recommended peptides together, see Post-PCAC 503A peptide pricing 2026, and for the three-peptide base see GLOW blend pricing.